Sabby Management’s DMK Pharmaceuticals DMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-3
Closed -$11K – 149
2022
Q2
$11K Buy
+3
New +$94 0.01% 122
2021
Q4
– Sell
-43
Closed -$293K – 220
2021
Q3
$293K Buy
+43
New +$3.15K 0.04% 133
2021
Q2
– Sell
-43
Closed -$285K – 194
2021
Q1
$285K Buy
43
+21
+95% +$1.64K 0.06% 123
2020
Q4
$76K Hold
22
– – 0.01% 97
2020
Q3
$122K Buy
+22
New +$1.3K 0.02% 113
2020
Q1
– Sell
-2
Closed -$8K – 113
2019
Q4
$8K Hold
2
– – ﹤0.01% 71
2019
Q3
$8K Buy
+2
New +$144 ﹤0.01% 91
2017
Q4
– Sell
-8
Closed -$300K – 194
2017
Q3
$300K Sell
8
-10
-56% -$3.55K 0.02% 119
2017
Q2
$651K Buy
+18
New +$5.39K 0.04% 123
2017
Q1
– Sell
-2
Closed -$42K – 332
2016
Q4
$42K Hold
2
– – ﹤0.01% 286
2016
Q3
$51K Buy
+2
New +$416 ﹤0.01% 300

Other funds holding DMK

Sabby Management's DMK Position: Q2 2020 in Review

Sabby Management sold out of DMK Pharmaceuticals (DMK) in Q2 2020, closing a stake of 1,260 shares — an estimated $32K sold.

Sabby Management first reported a position in DMK in Q4 2013 and held it in 5 quarters. The position peaked at $2.6M in Q4 2013. 47 funds tracked by Wall St. Rank hold DMK as of Q2 2020.

  • Sabby Management reported no remaining DMK Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Sabby Management sold 1,260 DMK Pharmaceuticals shares in Q2 2020, an estimated $32K.
  • Sabby Management first reported a position in DMK Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Sabby Management's DMK Pharmaceuticals position peaked at $2.6M in Q4 2013.
  • 47 funds tracked by Wall St. Rank held DMK Pharmaceuticals as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.